Today's After-Hours Movers

Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) 38.8% LOWER; For the fourth quarter, the Company expects Andexxa global net revenues to be approximately $28 million. For the full year 2019, the Company expects Andexxa global net revenues to be approximately $111 million. (*** consensus is $134 million)

Sportsmans Warehouse (Nasdaq: SPWH) 16.4% LOWER; For the fourth quarter of fiscal year 2019, net sales are now expected to be in the range of $250 million to $254 million based on same stores sales in the range of down 7.0% to down 6.0% compared to the corresponding period of fiscal year 2018. Adjusted net income is now expected to be in the range of $7.5 million to $9.3 million with adjusted earnings per diluted share now expected to be in the range of $0.17 to $0.21 on a weighted average of approximately 43.5 million common shares outstanding. (*Consensus sees Q4 EPS of $0.32 on revenue of $267.9 million)

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 14.5% HIGHER; announced positive results from ATI-450-PKPD-101, a Single Ascending Dose and Multiple Ascending Dose (SAD/MAD) Phase 1 clinical trial of the investigational compound ATI-450. Preliminary data demonstrated that ATI-450:

Moderna, Inc., (Nasdaq: MRNA) 12.9% HIGHER; announced positive seven-month interim safety and immunogenicity data after the third and final vaccination in the Phase 1 study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647). The findings build on the previously reported three-month interim analysis, after two vaccinations, announced at the Companys R&D Day in September 2019. Additionally, the Company announced that the first participant was dosed in the Phase 2 dose-confirmation study. mRNA-1647 is a wholly owned program in Modernas prophylactic vaccines portfolio.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) 10.2% HIGHER; announced topline positive safety and efficacy data from Cohort 3 and longer-term data from Cohort 2 of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus (AAV) gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. In Cohort 3 (n=3), there were two confirmed female responders as well a third potential male responder who requires longer-term follow-up to confirm response status. In Cohort 2, one female patient has newly demonstrated a response starting at Week 52 which was confirmed at Week 78. The two previously disclosed responders in Cohort 1 and Cohort 2 also remain clinically and metabolically stable at 104 and 78 weeks, respectively. Across all nine patients dosed in the study, up to six patients have demonstrated a response.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) 10% LOWER; announced that it has commenced an underwritten public offering of its common stock.

Urban Outfitters, Inc. (NASDAQ: URBN) 9.5% LOWER; holiday comparable Retail segment net sales increased 3%, driven by growth in the digital channel, partially offset by negative retail store sales.

T2 Biosystems, Inc. (NASDAQ: TTOO) 7.9% HIGHER; Fourth quarter total revenue of approximately $3.0 million, an increase of 67% compared to the prior year period.

SYNNEX Corporation (NYSE: SNX) 7% HIGHER; plan to separate into two publicly traded companies: comprising of SYNNEX Technology Solutions, a leading IT distribution, services and integrated solutions company, and Concentrix, a leading global CX solutions company. Immediately following the transaction, SYNNEX shareholders will own shares of both SYNNEX and Concentrix.

Aptinyx Inc. (Nasdaq: APTX) 6.9% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

WD-40 Co. (NASDAQ: WDFC) 5.1% LOWER; reported Q1 EPS of $0.88, $0.10 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $98.6 million versus the consensus estimate of $103.97 million. WD-40 Co. sees FY2020 EPS of $4.74-$4.83, versus the consensus of $4.79.

VOXX Int'l (NASDAQ: VOXX) 5% LOWER; reported Q3 EPS of $0.10, versus $0.50 reported last year. Revenue for the quarter came in at $110.1 million versus the consensus estimate of $129.64 million.

Simulations Plus (NASDAQ: SLP) 4.2% HIGHER; reported Q4 EPS of $0.11, $0.01 better than the analyst estimate of $0.10. Revenue for the quarter came in at $9.4 million versus the consensus estimate of $8.61 million.

KB Home (NYSE: KBH) 1.5% LOWER; reported Q4 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $1.56 billion versus the consensus estimate of $1.61 billion.